MetaStat, Inc. (MTST) MetaSite Breast Test Shown to Predict Metastasis in Breast Cancer Study
Systemic metastasis-focused life science company MetaStat announced that a study of nearly 500 female breast cancer patients has demonstrated the value of the company’s MetaSite Breast test in predicting metastatic disease. Albert Einstein College of Medicine of Yeshiva University and Weill Cornell Medical College collaborated on the sponsored study. MetaStat’s MetaSite Breast test is a mechanism-based assay that identifies the tumor microenvironment of metastasis (TMEM) and predicts the likelihood of whether a woman with breast cancer will develop a distant metastasis, including spread to the liver, lungs, bone, brain, and other organs. The assay identifies the microanatomic landmark where tumor…